The aim of the present study was to quantify the levels of SOCS5 and SOCS7 transcripts, as well as the plasmatic concentrations of IFN-γ, IL17, and IL16 in samples from MS patients treated with GA or IFN-β, and correlate them with the progression and severity of the disease. This evidence concerns the gene IL16 and myeloid sarcoma.